APEA PMHNP Certification Exam 2026/2027 ANCC PMHNP-BC & AANP-PMH Aligned | NGN-Integrated
APEA PMHNP Certification Exam
Actual Certification Exam | 2026/2027 Update
ANCC PMHNP-BC & AANP-PMH Aligned | NGN-Integrated Q&A
Advanced Practice Psychiatric Nursing | Pass Guaranteed - A+ Graded
Comprehensive 203-Question Certification Preparation Bank
Total Questions 203 Cognitive Distribution 20% Recall / 50% Application / 30% Analysis
Question Format Multiple Choice (A-D), NGN-Integrated
Style Distribution 70% Scenario / 20% Direct Recall / 10% Case Analysis
Sections 7 Domains Certification Alignment ANCC PMHNP-BC & AANP-PMH
Diagnostic Framework DSM-5-TR Approval Standard A+ Graded | Pass Guaranteed
Exam Overview: This comprehensive APEA PMHNP certification preparation bank reflects the 2026/2027 examination
blueprint aligned with ANCC PMHNP-BC and AANP-PMH standards. The exam integrates Next Generation NCLEX
(NGN) clinical judgment scenarios across seven core domains: (1) Neurobiology and Psychopharmacology, (2) Psychiatric
Assessment and Diagnosis, (3) Psychotherapeutic Interventions, (4) Psychopharmacologic Management Across the
Lifespan, (5) Mood, Psychotic, and Anxiety-Related Disorders, (6) Special Populations and Integrated Care, and (7) Ethics,
Legal Principles, and Professional Standards. Each question includes a verified correct answer with detailed rationale
grounded in DSM-5-TR criteria, neurobiological mechanisms, pharmacodynamics, evidence-based guidelines, and
advanced practice psychiatric nursing standards.
SECTION 1: Neurobiology, Psychopharmacology, and Foundational
Neuroscience
Neurotransmitter Systems, Receptor Mechanisms, Pharmacodynamics, Pharmacokinetics, & Neurobiological Hypotheses | Q1 -
Q45
Q1: A 24-year-old graduate student presents with new-onset auditory hallucinations telling him he is "being
watched." PMHNP recognizes that this positive symptom of schizophrenia is most directly linked to
dopamine hyperactivity in which pathway?
A. Tuberoinfundibular pathway
B. Mesolimbic pathway [CORRECT]
C. Nigrostriatal pathway
D. Mesocortical pathway
Correct Answer: B
Rationale: The mesolimbic pathway projects from the ventral tegmental area to the nucleus accumbens and is
hyperactive in schizophrenia, driving positive symptoms (hallucinations, delusions, disorganized thought). D2
antagonism in this pathway produces antipsychotic efficacy. The nigrostriatal pathway modulates movement (blockade
causes EPS); tuberoinfundibular controls prolactin (blockade causes hyperprolactinemia); mesocortical hypofunction
underlies negative and cognitive symptoms and is not improved by D2 antagonism.
A+ Graded | Pass Guaranteed | Verified Answers Page 1
,APEA PMHNP Certification Exam 2026/2027 ANCC PMHNP-BC & AANP-PMH Aligned | NGN-Integrated
Q2: A patient with chronic schizophrenia shows prominent negative symptoms (affective flattening, alogia,
avolition) despite optimal D2 blockade. The PMHNP recognizes that these symptoms are associated with
hypofunction in which dopamine pathway?
A. Mesolimbic pathway
B. Mesocortical pathway [CORRECT]
C. Nigrostriatal pathway
D. Tuberoinfundibular pathway
Correct Answer: B
Rationale: The mesocortical pathway projects from the ventral tegmental area to the prefrontal cortex;
hypodopaminergia here underlies negative and cognitive symptoms of schizophrenia. D2 antagonists worsen or fail to
improve these symptoms, explaining why patients on first-generation antipsychotics often show persistent negative
symptoms. Glutamatergic agents (e.g., NMDA modulators) and second-generation antipsychotics with broader
pharmacology are being investigated to address this gap. The mesolimbic pathway is hyperactive (positive symptoms),
not hypoactive.
Q3: A 35-year-old woman with schizoaffective disorder develops galactorrhea and amenorrhea after starting
risperidone. The PMHNP understands this adverse effect results from D2 blockade in which pathway?
A. Mesolimbic pathway
B. Nigrostriatal pathway
C. Tuberoinfundibular pathway [CORRECT]
D. Mesocortical pathway
Correct Answer: C
Rationale: The tuberoinfundibular pathway projects from the hypothalamus to the pituitary; dopamine normally
inhibits prolactin release here. D2 blockade by antipsychotics (especially risperidone) removes this inhibition, causing
hyperprolactinemia, galactorrhea, amenorrhea, gynecomastia, and sexual dysfunction. Risperidone carries the highest
prolactin elevation risk among atypicals. Management options include dose reduction, switching to a prolactin-sparing
agent (aripiprazole), or adding aripiprazole as augmentation. The nigrostriatal pathway concerns movement (EPS); the
mesolimbic/mesocortical concern positive/negative symptoms.
Q4: A patient develops acute dystonia after the first dose of haloperidol. The PMHNP recognizes this adverse
effect is caused by D2 blockade in which pathway?
A. Nigrostriatal pathway [CORRECT]
B. Mesolimbic pathway
C. Tuberoinfundibular pathway
D. Mesocortical pathway
Correct Answer: A
Rationale: The nigrostriatal pathway projects from the substantia nigra to the striatum and modulates voluntary
movement. D2 blockade here produces movement disorders: acute dystonia, akathisia, parkinsonism, and tardive
dyskinesia (EPS). First-generation antipsychotics (haloperidol, chlorpromazine) carry much higher EPS risk than
second-generation agents because of stronger D2 affinity and less 5-HT2A antagonism. Treatment of acute dystonia
includes IM/IV diphenhydramine or benztropine. Switching to a second-generation antipsychotic with lower D2 affinity
helps prevent recurrence.
A+ Graded | Pass Guaranteed | Verified Answers Page 2
,APEA PMHNP Certification Exam 2026/2027 ANCC PMHNP-BC & AANP-PMH Aligned | NGN-Integrated
Q5: A 28-year-old presents with depressed mood, anhedonia, and chronic diffuse musculoskeletal pain
unresponsive to NSAIDs. The PMHNP selects duloxetine. Which mechanism best explains its dual benefit for
both pain and depressive symptoms?
A. Selective serotonin reuptake inhibition only
B. Balanced serotonin and norepinephrine reuptake inhibition—descending noradrenergic pathways
modulate pain, while dual monoamine enhancement treats depressive symptoms [CORRECT]
C. Dopamine reuptake inhibition enhancing reward pathways
D. GABA-A receptor potentiation providing anxiolysis
Correct Answer: B
Rationale: Duloxetine is an SNRI with balanced inhibition of both serotonin and norepinephrine transporters. The
descending noradrenergic pathways from the brainstem to the dorsal horn inhibit nociceptive transmission, addressing
neuropathic and chronic musculoskeletal pain. Simultaneously, dual monoamine enhancement in limbic and prefrontal
circuits treats depressive symptoms. This dual mechanism is why SNRIs (duloxetine, venlafaxine, milnacipran) are
preferred in melancholic depression with comorbid chronic pain, fibromyalgia, or diabetic neuropathy. SSRIs lack
sufficient noradrenergic activity for analgesia.
Q6: A PMHNP is selecting an antidepressant for a 45-year-old man with melancholic depression
characterized by severe anhedonia, weight loss, and psychomotor retardation. Which pharmacologic property
makes an SNRI particularly suited for melancholic depression?
A. Selective dopamine reuptake inhibition
B. Dual serotonin-norepinephrine transporter blockade addressing melancholic features [CORRECT]
C. Selective 5-HT2C antagonism increasing dopamine release
D. Alpha-2 adrenergic auto-receptor antagonism
Correct Answer: B
Rationale: Melancholic depression is characterized by profound anhedonia, severe psychomotor disturbance, weight
loss, and excessive guilt. SNRIs (venlafaxine, duloxetine, desvenlafaxine, milnacipran, levomilnacipran) provide
balanced serotonin and norepinephrine transporter blockade, addressing both the serotonergic deficits underlying
mood/anxiety and the noradrenergic deficits underlying energy, motivation, and concentration. TCAs (also SNRIs
pharmacologically) are similarly effective for melancholic depression but are less safe in overdose. SSRIs may be less
effective in severe melancholic presentations. NDRIs (bupropion) target dopamine and norepinephrine but lack
serotonergic action.
Q7: A PMHNP is educating a patient starting bupropion. The PMHNP explains that bupropion is best
classified as which type of antidepressant based on its mechanism?
A. Selective serotonin reuptake inhibitor (SSRI)
B. Serotonin-norepinephrine reuptake inhibitor (SNRI)
C. Norepinephrine-dopamine reuptake inhibitor (NDRI) [CORRECT]
D. 5-HT2A antagonist and SARI
Correct Answer: C
Rationale: Bupropion is a norepinephrine-dopamine reuptake inhibitor (NDRI), blocking NET and DAT without
affecting SERT. This profile makes it useful for depression with prominent anergia, hypersomnia, and cognitive
slowing—often called "atypical depression." Bupropion is also used for smoking cessation (reduces nicotine craving via
dopaminergic action) and as augmentation for SSRI-related sexual dysfunction. It is NOT a first-line choice for anxiety
disorders (can be stimulating and worsen anxiety) and is contraindicated in seizure disorders and eating disorders due to
seizure-lowering threshold effects.
A+ Graded | Pass Guaranteed | Verified Answers Page 3
, APEA PMHNP Certification Exam 2026/2027 ANCC PMHNP-BC & AANP-PMH Aligned | NGN-Integrated
Q8: A patient with MDD and comorbid insomnia and sexual dysfunction asks about an antidepressant that
might address both depression and sleep. The PMHNP considers mirtazapine, which works primarily as:
A. A selective serotonin reuptake inhibitor
B. A norepinephrine-doprine reuptake inhibitor
C. A presynaptic alpha-2 antagonist and 5-HT2A/5-HT2C/5-HT3 antagonist (tetracyclic atypical)
[CORRECT]
D. A reversible inhibitor of MAO-A
Correct Answer: C
Rationale: Mirtazapine is a tetracyclic atypical antidepressant whose primary mechanism is presynaptic alpha-2
adrenergic receptor antagonism, which increases norepinephrine and serotonin release. It also blocks 5-HT2A (improves
sleep architecture), 5-HT2C (reduces anxiety, may increase appetite), and 5-HT3 (reduces nausea/GI side effects). The
net clinical profile: sedation (via H1 antagonism), improved sleep, appetite stimulation, and minimal sexual dysfunction
compared with SSRIs. Mirtazapine is useful for depressed patients with insomnia, weight loss, and anxiety. Weight gain
is a common side effect.
Q9: A 42-year-old patient on fluoxetine 40 mg daily for MDD develops worsening anxiety, agitation, tremor,
and hyperreflexia 3 days after tramadol is added for post-surgical pain. The PMHNP suspects serotonin
syndrome. Which pharmacologic mechanism is most responsible?
A. Additive anticholinergic effects causing delirium
B. Synergistic serotonin reuptake inhibition—fluoxetine (SSRI) + tramadol (SNRI + serotonergic
opioid) cause excessive serotonergic activity [CORRECT]
C. CYP2D6 inhibition increasing tramadol active metabolite
D. NMDA receptor antagonism causing dissociation
Correct Answer: B
Rationale: Serotonin syndrome results from excessive central serotonergic activity, classically with combinations of
serotonergic agents. Fluoxetine is a potent SSRI; tramadol is a serotonin-norepinephrine reuptake inhibitor AND a
serotonergic opioid (releases serotonin). Combined, they dangerously elevate synaptic serotonin. Classic triad:
neuromuscular hyperactivity (hyperreflexia, clonus, tremor), autonomic instability (hyperthermia, tachycardia,
hypertension), and altered mental status (agitation, confusion). Management: discontinue both agents immediately,
supportive care, cyproheptadine (5-HT2A antagonist) for moderate-severe cases. Benzodiazepines for agitation. The
interaction is pharmacodynamic, not purely CYP-mediated.
Q10: A PMHNP is comparing antipsychotic receptor binding profiles. Aripiprazole differs from haloperidol
because aripiprazole acts as:
A. A full D2 agonist
B. A partial D2 agonist with stabilizing effect on dopamine activity [CORRECT]
C. A pure D2 antagonist with high EPS risk
D. A selective 5-HT1A antagonist
Correct Answer: B
Rationale: Aripiprazole is a partial D2 agonist (third-generation antipsychotic). Its intrinsic activity at D2 receptors is
moderate, so it acts as a functional antagonist when endogenous dopamine is high (suppressing positive symptoms in
mesolimbic pathway) and as a functional agonist when endogenous dopamine is low (supporting prefrontal
dopaminergic activity in mesocortical pathway). This "dopamine stabilizing" effect explains low EPS risk and low
prolactin elevation. Aripiprazole is also a partial 5-HT1A agonist and 5-HT2A antagonist. Full D2 antagonists like
haloperidol cause significant EPS, hyperprolactinemia, and risk of tardive dyskinesia.
A+ Graded | Pass Guaranteed | Verified Answers Page 4
APEA PMHNP Certification Exam
Actual Certification Exam | 2026/2027 Update
ANCC PMHNP-BC & AANP-PMH Aligned | NGN-Integrated Q&A
Advanced Practice Psychiatric Nursing | Pass Guaranteed - A+ Graded
Comprehensive 203-Question Certification Preparation Bank
Total Questions 203 Cognitive Distribution 20% Recall / 50% Application / 30% Analysis
Question Format Multiple Choice (A-D), NGN-Integrated
Style Distribution 70% Scenario / 20% Direct Recall / 10% Case Analysis
Sections 7 Domains Certification Alignment ANCC PMHNP-BC & AANP-PMH
Diagnostic Framework DSM-5-TR Approval Standard A+ Graded | Pass Guaranteed
Exam Overview: This comprehensive APEA PMHNP certification preparation bank reflects the 2026/2027 examination
blueprint aligned with ANCC PMHNP-BC and AANP-PMH standards. The exam integrates Next Generation NCLEX
(NGN) clinical judgment scenarios across seven core domains: (1) Neurobiology and Psychopharmacology, (2) Psychiatric
Assessment and Diagnosis, (3) Psychotherapeutic Interventions, (4) Psychopharmacologic Management Across the
Lifespan, (5) Mood, Psychotic, and Anxiety-Related Disorders, (6) Special Populations and Integrated Care, and (7) Ethics,
Legal Principles, and Professional Standards. Each question includes a verified correct answer with detailed rationale
grounded in DSM-5-TR criteria, neurobiological mechanisms, pharmacodynamics, evidence-based guidelines, and
advanced practice psychiatric nursing standards.
SECTION 1: Neurobiology, Psychopharmacology, and Foundational
Neuroscience
Neurotransmitter Systems, Receptor Mechanisms, Pharmacodynamics, Pharmacokinetics, & Neurobiological Hypotheses | Q1 -
Q45
Q1: A 24-year-old graduate student presents with new-onset auditory hallucinations telling him he is "being
watched." PMHNP recognizes that this positive symptom of schizophrenia is most directly linked to
dopamine hyperactivity in which pathway?
A. Tuberoinfundibular pathway
B. Mesolimbic pathway [CORRECT]
C. Nigrostriatal pathway
D. Mesocortical pathway
Correct Answer: B
Rationale: The mesolimbic pathway projects from the ventral tegmental area to the nucleus accumbens and is
hyperactive in schizophrenia, driving positive symptoms (hallucinations, delusions, disorganized thought). D2
antagonism in this pathway produces antipsychotic efficacy. The nigrostriatal pathway modulates movement (blockade
causes EPS); tuberoinfundibular controls prolactin (blockade causes hyperprolactinemia); mesocortical hypofunction
underlies negative and cognitive symptoms and is not improved by D2 antagonism.
A+ Graded | Pass Guaranteed | Verified Answers Page 1
,APEA PMHNP Certification Exam 2026/2027 ANCC PMHNP-BC & AANP-PMH Aligned | NGN-Integrated
Q2: A patient with chronic schizophrenia shows prominent negative symptoms (affective flattening, alogia,
avolition) despite optimal D2 blockade. The PMHNP recognizes that these symptoms are associated with
hypofunction in which dopamine pathway?
A. Mesolimbic pathway
B. Mesocortical pathway [CORRECT]
C. Nigrostriatal pathway
D. Tuberoinfundibular pathway
Correct Answer: B
Rationale: The mesocortical pathway projects from the ventral tegmental area to the prefrontal cortex;
hypodopaminergia here underlies negative and cognitive symptoms of schizophrenia. D2 antagonists worsen or fail to
improve these symptoms, explaining why patients on first-generation antipsychotics often show persistent negative
symptoms. Glutamatergic agents (e.g., NMDA modulators) and second-generation antipsychotics with broader
pharmacology are being investigated to address this gap. The mesolimbic pathway is hyperactive (positive symptoms),
not hypoactive.
Q3: A 35-year-old woman with schizoaffective disorder develops galactorrhea and amenorrhea after starting
risperidone. The PMHNP understands this adverse effect results from D2 blockade in which pathway?
A. Mesolimbic pathway
B. Nigrostriatal pathway
C. Tuberoinfundibular pathway [CORRECT]
D. Mesocortical pathway
Correct Answer: C
Rationale: The tuberoinfundibular pathway projects from the hypothalamus to the pituitary; dopamine normally
inhibits prolactin release here. D2 blockade by antipsychotics (especially risperidone) removes this inhibition, causing
hyperprolactinemia, galactorrhea, amenorrhea, gynecomastia, and sexual dysfunction. Risperidone carries the highest
prolactin elevation risk among atypicals. Management options include dose reduction, switching to a prolactin-sparing
agent (aripiprazole), or adding aripiprazole as augmentation. The nigrostriatal pathway concerns movement (EPS); the
mesolimbic/mesocortical concern positive/negative symptoms.
Q4: A patient develops acute dystonia after the first dose of haloperidol. The PMHNP recognizes this adverse
effect is caused by D2 blockade in which pathway?
A. Nigrostriatal pathway [CORRECT]
B. Mesolimbic pathway
C. Tuberoinfundibular pathway
D. Mesocortical pathway
Correct Answer: A
Rationale: The nigrostriatal pathway projects from the substantia nigra to the striatum and modulates voluntary
movement. D2 blockade here produces movement disorders: acute dystonia, akathisia, parkinsonism, and tardive
dyskinesia (EPS). First-generation antipsychotics (haloperidol, chlorpromazine) carry much higher EPS risk than
second-generation agents because of stronger D2 affinity and less 5-HT2A antagonism. Treatment of acute dystonia
includes IM/IV diphenhydramine or benztropine. Switching to a second-generation antipsychotic with lower D2 affinity
helps prevent recurrence.
A+ Graded | Pass Guaranteed | Verified Answers Page 2
,APEA PMHNP Certification Exam 2026/2027 ANCC PMHNP-BC & AANP-PMH Aligned | NGN-Integrated
Q5: A 28-year-old presents with depressed mood, anhedonia, and chronic diffuse musculoskeletal pain
unresponsive to NSAIDs. The PMHNP selects duloxetine. Which mechanism best explains its dual benefit for
both pain and depressive symptoms?
A. Selective serotonin reuptake inhibition only
B. Balanced serotonin and norepinephrine reuptake inhibition—descending noradrenergic pathways
modulate pain, while dual monoamine enhancement treats depressive symptoms [CORRECT]
C. Dopamine reuptake inhibition enhancing reward pathways
D. GABA-A receptor potentiation providing anxiolysis
Correct Answer: B
Rationale: Duloxetine is an SNRI with balanced inhibition of both serotonin and norepinephrine transporters. The
descending noradrenergic pathways from the brainstem to the dorsal horn inhibit nociceptive transmission, addressing
neuropathic and chronic musculoskeletal pain. Simultaneously, dual monoamine enhancement in limbic and prefrontal
circuits treats depressive symptoms. This dual mechanism is why SNRIs (duloxetine, venlafaxine, milnacipran) are
preferred in melancholic depression with comorbid chronic pain, fibromyalgia, or diabetic neuropathy. SSRIs lack
sufficient noradrenergic activity for analgesia.
Q6: A PMHNP is selecting an antidepressant for a 45-year-old man with melancholic depression
characterized by severe anhedonia, weight loss, and psychomotor retardation. Which pharmacologic property
makes an SNRI particularly suited for melancholic depression?
A. Selective dopamine reuptake inhibition
B. Dual serotonin-norepinephrine transporter blockade addressing melancholic features [CORRECT]
C. Selective 5-HT2C antagonism increasing dopamine release
D. Alpha-2 adrenergic auto-receptor antagonism
Correct Answer: B
Rationale: Melancholic depression is characterized by profound anhedonia, severe psychomotor disturbance, weight
loss, and excessive guilt. SNRIs (venlafaxine, duloxetine, desvenlafaxine, milnacipran, levomilnacipran) provide
balanced serotonin and norepinephrine transporter blockade, addressing both the serotonergic deficits underlying
mood/anxiety and the noradrenergic deficits underlying energy, motivation, and concentration. TCAs (also SNRIs
pharmacologically) are similarly effective for melancholic depression but are less safe in overdose. SSRIs may be less
effective in severe melancholic presentations. NDRIs (bupropion) target dopamine and norepinephrine but lack
serotonergic action.
Q7: A PMHNP is educating a patient starting bupropion. The PMHNP explains that bupropion is best
classified as which type of antidepressant based on its mechanism?
A. Selective serotonin reuptake inhibitor (SSRI)
B. Serotonin-norepinephrine reuptake inhibitor (SNRI)
C. Norepinephrine-dopamine reuptake inhibitor (NDRI) [CORRECT]
D. 5-HT2A antagonist and SARI
Correct Answer: C
Rationale: Bupropion is a norepinephrine-dopamine reuptake inhibitor (NDRI), blocking NET and DAT without
affecting SERT. This profile makes it useful for depression with prominent anergia, hypersomnia, and cognitive
slowing—often called "atypical depression." Bupropion is also used for smoking cessation (reduces nicotine craving via
dopaminergic action) and as augmentation for SSRI-related sexual dysfunction. It is NOT a first-line choice for anxiety
disorders (can be stimulating and worsen anxiety) and is contraindicated in seizure disorders and eating disorders due to
seizure-lowering threshold effects.
A+ Graded | Pass Guaranteed | Verified Answers Page 3
, APEA PMHNP Certification Exam 2026/2027 ANCC PMHNP-BC & AANP-PMH Aligned | NGN-Integrated
Q8: A patient with MDD and comorbid insomnia and sexual dysfunction asks about an antidepressant that
might address both depression and sleep. The PMHNP considers mirtazapine, which works primarily as:
A. A selective serotonin reuptake inhibitor
B. A norepinephrine-doprine reuptake inhibitor
C. A presynaptic alpha-2 antagonist and 5-HT2A/5-HT2C/5-HT3 antagonist (tetracyclic atypical)
[CORRECT]
D. A reversible inhibitor of MAO-A
Correct Answer: C
Rationale: Mirtazapine is a tetracyclic atypical antidepressant whose primary mechanism is presynaptic alpha-2
adrenergic receptor antagonism, which increases norepinephrine and serotonin release. It also blocks 5-HT2A (improves
sleep architecture), 5-HT2C (reduces anxiety, may increase appetite), and 5-HT3 (reduces nausea/GI side effects). The
net clinical profile: sedation (via H1 antagonism), improved sleep, appetite stimulation, and minimal sexual dysfunction
compared with SSRIs. Mirtazapine is useful for depressed patients with insomnia, weight loss, and anxiety. Weight gain
is a common side effect.
Q9: A 42-year-old patient on fluoxetine 40 mg daily for MDD develops worsening anxiety, agitation, tremor,
and hyperreflexia 3 days after tramadol is added for post-surgical pain. The PMHNP suspects serotonin
syndrome. Which pharmacologic mechanism is most responsible?
A. Additive anticholinergic effects causing delirium
B. Synergistic serotonin reuptake inhibition—fluoxetine (SSRI) + tramadol (SNRI + serotonergic
opioid) cause excessive serotonergic activity [CORRECT]
C. CYP2D6 inhibition increasing tramadol active metabolite
D. NMDA receptor antagonism causing dissociation
Correct Answer: B
Rationale: Serotonin syndrome results from excessive central serotonergic activity, classically with combinations of
serotonergic agents. Fluoxetine is a potent SSRI; tramadol is a serotonin-norepinephrine reuptake inhibitor AND a
serotonergic opioid (releases serotonin). Combined, they dangerously elevate synaptic serotonin. Classic triad:
neuromuscular hyperactivity (hyperreflexia, clonus, tremor), autonomic instability (hyperthermia, tachycardia,
hypertension), and altered mental status (agitation, confusion). Management: discontinue both agents immediately,
supportive care, cyproheptadine (5-HT2A antagonist) for moderate-severe cases. Benzodiazepines for agitation. The
interaction is pharmacodynamic, not purely CYP-mediated.
Q10: A PMHNP is comparing antipsychotic receptor binding profiles. Aripiprazole differs from haloperidol
because aripiprazole acts as:
A. A full D2 agonist
B. A partial D2 agonist with stabilizing effect on dopamine activity [CORRECT]
C. A pure D2 antagonist with high EPS risk
D. A selective 5-HT1A antagonist
Correct Answer: B
Rationale: Aripiprazole is a partial D2 agonist (third-generation antipsychotic). Its intrinsic activity at D2 receptors is
moderate, so it acts as a functional antagonist when endogenous dopamine is high (suppressing positive symptoms in
mesolimbic pathway) and as a functional agonist when endogenous dopamine is low (supporting prefrontal
dopaminergic activity in mesocortical pathway). This "dopamine stabilizing" effect explains low EPS risk and low
prolactin elevation. Aripiprazole is also a partial 5-HT1A agonist and 5-HT2A antagonist. Full D2 antagonists like
haloperidol cause significant EPS, hyperprolactinemia, and risk of tardive dyskinesia.
A+ Graded | Pass Guaranteed | Verified Answers Page 4
